Medical News

RSS

AHF reiterates its disappointment over the presentation of Thai HIV vaccine study data

In anticipation of today’s controversial presentation of the Thai HIV vaccine study data at the AIDS Vaccine Conference in Paris, AIDS Healthcare Foundation (AHF) reiterated its disappointment at the news that data that seriously undermined the purported success of the trial were not released publicly when other, more favorable data were reported late last month.

20 Oct 2009

Pharmacy services still in demand despite recession

Despite the onset of an economic recession during 2008, pharmacy services were still in demand due to their value in the health care delivery system. The average community pharmacy saw its total sales increase by 7.6% to $3.9 million.

20 Oct 2009

NCCN Guidelines for Acute Myeloid Leukemia updated

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia, a cancer that starts inside the bone marrow and the most common acute leukemia affecting adults.

20 Oct 2009

IntegraMed America expands its Attain IVF treatment financing offerings

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced that it has expanded its Attain™ IVF (In Vitro Fertilization) family of treatment financing offerings to include the Attain IVF Multi-Cycle Program.

20 Oct 2009

Aspect Medical Systems to present a complete family of BIS monitoring technologies at ASA meeting

The American Society of Anesthesiologists (ASA) Annual Meeting will feature 62 scientific presentations that reference BIS® monitoring when it convenes on October 17-21, 2009 in New Orleans. BIS-related research will cover a broad range of applications for BIS monitoring, including initial results from studies conducted as part of a comparative effectiveness research collaboration with the Cleveland Clinic as well as findings from a study evaluating use of a Composite Variability Index (CVI) that is based on BIS parameters.

20 Oct 2009

Remote-controlled robot for testing visual prosthesis

Scientists at the California Institute of Technology (Caltech) have created a remote-controlled robot that is able to simulate the "visual" experience of a blind person who has been implanted with a visual prosthesis, such as an artificial retina.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

PhRMA calls for appropriate incentives for continued biotechnology innovation

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding appropriate incentives for continued biotechnology innovation:

20 Oct 2009

Teacher participation in research experience program produces a significaant increase in student achievement

The notion that training teachers in the rigors of hands-on science will directly improve their students' academic performance now has real data behind it: Research assembled over the last decade - now published in the Oct. 16 issue of Science - shows that high school students' pass rate on New York State standardized tests, called Regents examinations, can be significantly improved if they are among the lucky few to study under a teacher trained in Columbia University's Summer Research Program for Science Teachers.

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

Repligen Corporation reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the sensitivity and specificity of RG1068 in conjunction with MRI for the detection of pancreatic duct abnormalities compared to MRI alone.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Preliminary findings from EDC survey presented at DIA 3rd Annual Clinical Forum

Preliminary findings from a new survey on electronic data capture (EDC) use in clinical trials were presented today at the Drug Information Association's (DIA) 3rd Annual Clinical Forum in Nice, France. The survey, titled "Investigational Site Perspectives on Clinical Trial Information Systems," is the first update to a 2001 survey published on the topic.

20 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan Corporation, plc and Biogen Idec today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

20 Oct 2009

Medical Marijuana offers "Turnkey Collective Solution" for collectives to conform to state laws

Medical Marijuana, Inc. is the ONLY company that provides the specific solutions the government is seeking in order for all collectives and co-ops to be in total compliance with state laws and city/county ordinances. Their revolutionary patent pending Tax Remittance Card and patent pending Inventory Management System and Supply Chain Network provides all of the tools necessary for regulatory authorities and industry operators alike to manage compliance efficiently and effectively.

20 Oct 2009

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

On October 15, 2009, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a joint warning letter to a Web site marketing fraudulent supplements that claim to help prevent the spread of the 2009 H1N1 influenza virus.

20 Oct 2009

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

This study demonstrates that over 6 weeks of treatment, patients with melancholic depression and medical comorbidity (MC) (specifically cardiovascular or endocrinological MC) had poorer treatment response and a worse functional outcome as opposed to their counterparts without MC. Interestingly, these effects were not related to various antidepressant treatment regimens.

20 Oct 2009

Medical News

AHF reiterates its disappointment over the presentation of Thai HIV vaccine study data

Pharmacy services still in demand despite recession

NCCN Guidelines for Acute Myeloid Leukemia updated

IntegraMed America expands its Attain IVF treatment financing offerings

Aspect Medical Systems to present a complete family of BIS monitoring technologies at ASA meeting

Remote-controlled robot for testing visual prosthesis

Two high blood pressure medicines effective in treating stable ischemic heart disease

PhRMA calls for appropriate incentives for continued biotechnology innovation

Teacher participation in research experience program produces a significaant increase in student achievement

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Preliminary findings from EDC survey presented at DIA 3rd Annual Clinical Forum

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

ImmunoCellular Therapeutics files a provisional patent application

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Medical Marijuana offers "Turnkey Collective Solution" for collectives to conform to state laws

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News